Maat Pharma (XPAR:MAAT) 3-Month Share Buyback Ratio: 0.00% (As of Dec. 2025 )

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:MAAT Maat Pharma SA XPAR:MAAT
29 GF Score
Price €2.94
GF Value €10.85
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Maat Pharma 3-Month Share Buyback Ratio?

Maat Pharma XPAR:MAAT -0.84% 29 3-Month Share Buyback Ratio is 0.00 as of Dec. 2025. GuruFocus rates XPAR:MAAT with a GF Score™ of 29/100 and a GF Value™ of €10.85 (Possible Value Trap). The stock has 3 warning signs investors should review.

3-Month Share Buyback Ratio only apply to companies whose reporting frequency is 3 months.

XPAR:MAAT
29GF Score
Maat Pharma SA XPAR:MAAT
3-Month Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a 3-Month Share Buyback Ratio of 0.00 mean?
Maat Pharma (XPAR:MAAT) has a 3-Month Share Buyback Ratio of 0.00 as of Dec. 2025. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Maat Pharma and its competitors.
Is Maat Pharma's 3-Month Share Buyback Ratio too high?
Maat Pharma's current 3-Month Share Buyback Ratio is 0.00. Overall, Maat Pharma has a GF Score™ of 29/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Maat Pharma's 3-Month Share Buyback Ratio compare to VRTX and REGN?
Maat Pharma's 3-Month Share Buyback Ratio of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Month Share Buyback Ratio for a Biotechnology company?
A good 3-Month Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Month Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Month Share Buyback Ratio mean?
A high 3-Month Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Maat Pharma and its competitors. Maat Pharma's current 3-Month Share Buyback Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maat Pharma stock overvalued right now?
Based on GuruFocus' analysis, Maat Pharma (XPAR:MAAT) is currently considered Possible Value Trap. The stock's GF Value™ is €10.85, compared to a current price of €2.94 — trading 72.9% below its estimated fair value. The current 3-Month Share Buyback Ratio is 0.00. Maat Pharma's overall GF Score™ is 29/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Month Share Buyback Ratio calculated?
3-Month Share Buyback Ratio is calculated from a company's financial statements. For Maat Pharma (XPAR:MAAT), the current 3-Month Share Buyback Ratio is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Maat Pharma (XPAR:MAAT) Overvalued in 2026?

Based on GuruFocus' analysis, Maat Pharma stock appears to be undervalued. The current stock price of €2.94 is trading 72.9% below its estimated GF Value™ of €10.85. GuruFocus considers Maat Pharma to be Possible Value Trap.

Key valuation signals for XPAR:MAAT:

  • 3-Month Share Buyback Ratio: 0.00
  • GF Value™: €10.85 vs. price of €2.94 (72.9% below fair value)
  • GF Score™: 29/100 with 3 warning signs

No single metric tells the full story. See the XPAR:MAAT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Maat Pharma Business Description

Other Exchanges 4RD:Germany
Address 70 Avenue Tony Garnier, Lyon, FRA, 69007
Maat Pharma SA is a french clinical stage biotech and a pioneer in the development of microbiome based ecosystem therapies dedicated to improving survival outcomes for patients with cancer.
29GF Score

Get the complete analysis for XPAR:MAAT

3-Month Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.94
Price
€10.85
GF Value